Natural born killers: NK cells drafted into the cancer fight.
O'Hanlon
Leslie Harris
LH
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000276:immunology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005805:Genes, MHC Class I; D006801:Humans; D007376:Interleukin-2 / Q000627:therapeutic use; D007694:Killer Cells, Natural / Q000276:immunology*; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology*; D011956:Receptors, Cell Surface / Q000276:immunology; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D007376:Interleukin-2; D011956:Receptors, Cell Surface; D000069283:Rituximab